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Abstract:  The impact of fixed-dose combination (FDC) products on adherence to other, 
non-fixed regimen components has not been examined. We compared adherence to a third 
antiretroviral (ART) component among patients receiving a nucleoside reverse transcriptase 
inhibitor (NRTI) backbone consisting of the FDC Epzicom®, GlaxoSmithKline Inc, Research 
Triangle Park, NC (abacavir sulfate 600 mg + lamivudine 300 mg; FDC group) versus NRTI 
combinations taken as two separate pills (NRTI Combo group) using data from a national 
sample  of  30  health  plans  covering  approximately  38  million  lives  from  1997  to  2005. 
Adherence was measured as the medication possession ratio (MPR). Multivariate logistic 
regression compared treatment groups based on the likelihood of achieving $95% adherence, 
with sensitivity analyses using alternative thresholds. MPR was assessed as a continuous 
variable using multivariate linear regression. Covariates included age, gender, insurance payer 
type, year of study drug initiation, presence of mental health and substance abuse disorders, 
and third agent class. The study sample consisted of 650 FDC and 1947 NRTI Combo patients. 
Unadjusted mean adherence to the third agent was higher in the FDC group than the NRTI 
Combo group (0.92 vs 0.85; P , 0.0001). In regression analyses, FDC patients were 48% and 
39% more likely to achieve 95% and 90% third agent adherence, respectively (P # 0.03). None 
of the other MPR specifications achieved comparable results. Among managed care patients, 
use of an FDC appears to substantially improve adherence to a third regimen component and 
thus the likelihood of achieving the accepted standard for adherence to HIV therapy of 95%.
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Introduction
Mortality and morbidity associated with HIV disease are dramatically reduced through 
the use of combination antiretroviral therapy (ART), commonly comprised of two 
nucleoside reverse transcriptase inhibitors (NRTIs) and either a non-NRTI (NNRTI) 
or a protease inhibitor (PI).1,2 The latter is often “boosted” with a low-dose of the PI, 
ritonavir (Norvir, Abbott Laboratories, Abbott Park, IL). ART regimens containing a 
boosted PI may consist of up to four separate pills, with several dosing frequencies 
and requirements. However, more compact ART regimens can be created by t  aking 
advantage of fixed-dose combination (FDC) products which consist of two or more anti-
retroviral drugs in a single tablet.
Since the introduction of the first FDC antiretroviral product, FDCs have become 
a mainstay in the treatment of HIV . The chief advantage of FDCs lies in simplifying a 
patient’s regimen. In addition to reducing pill burden, many FDCs also have reduced 
dosing frequency and/or dosing requirements compared to other drugs in the FDC’s 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
155
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S28482Patient Preference and Adherence 2012:6
therapeutic class. These factors work together to increase the 
likelihood of adherence.3 To date, most FDC introductions 
for HIV treatment have consisted of combinations of NRTIs 
which form the backbone of the ART regimen.4 Patients 
receiving an NRTI FDC would require a separate NNRTI 
or PI component.
In HIV, perhaps more than other chronic diseases, 
regimen adherence is a critical and necessary component 
of successful treatment. Previous studies have documented 
that adherence rates in excess of 95% are required in order to 
achieve a high likelihood of reaching an undetectable plasma 
HIV RNA level (viral load), a primary objective of ART.4–6 
This high level of adherence is needed throughout the course 
of therapy to maintain undetectable viral load and to protect 
against the development of viral resistance to regimen com-
ponents. Poor adherence and the subsequent development of 
resistance is a primary cause of regimen failure.4
FDCs have been associated with improved adherence 
compared to their separate components in both clinical trial 
and observational studies. For example, adherence to the 
FDC containing lamivudine 150 mg + zidovudine 300 mg 
(Combivir®, GlaxoSmithKline Inc, Research Triangle Park, 
NC) has been shown to be higher than adherence to its indi-
vidual components.7,8 Similar results have been documented 
for FDCs in other therapeutic areas.9 In addition, it has been 
shown that a reduction in the total number of pills prescribed 
can improve adherence to the overall HIV regimen10–12 and 
suggested that improved adherence to an ART backbone also 
may result in improved regimen adherence.13–15 Yet, specific 
evidence of a spillover adherence effect on the remaining 
regimen components among individuals receiving FDC-
based ART regimens is lacking. We compared adherence 
to the remaining regimen component among individuals 
receiving ART including an NRTI backbone containing 
an FDC of abacavir sulfate (ABC) 600 mg + lamivudine 
(3TC) 300 mg (Epzicom, GlaxoSmithKline Inc, Research 
Triangle Park, NC) versus NRTI combinations given as two 
separate pills.
Materials and methods
Data and patients
Data were taken from the Integrated Health Care Information 
Services (IHCIS, Waltham, MA) Managed Care Benchmark 
Database, which contains medical (inpatient, outpatient, phy-
sician, other ancillary) and pharmacy claims from a national 
sample of 30 managed care health plans covering approxi-
mately 38 million lives in the United States over the period 
1997 to 2005.16 The IHCIS database has a r  epresentative 
distribution of age and gender compared with national 
enrollment in managed care plans. Geographic representa-
tion, however, is biased toward the East Coast. Patient-level 
records in the IHCIS database include demographics and 
information on benefits eligibility, and periods of health plan 
enrollment. Claims records in the IHCIS database contain 
detailed information on diagnoses, hospitalizations, diagnos-
tic testing, therapeutic procedures, inpatient and outpatient 
physician services, prescription drug use, and cost data in the 
form of standardized managed care reimbursed amounts for 
each service. All claims in the IHCIS database were linked 
using unique patient identifiers and arranged in chronologi-
cal order, thereby providing a detailed longitudinal file of all 
medical and pharmacy services utilized by each patient.
All patients in the IHCIS database with at least one phar-
macy claim for Epzicom or for two or more components of 
an NRTI backbone as separate pills were eligible for study 
inclusion. For each patient, the date of the first prescrip-
tion claim for any of these agents was designated the index 
date. Patients initiating Epzicom were designated the FDC 
group, while subjects receiving separate NRTI components 
on the index date were designated the NRTI Combo group. 
Patients in the NRTI Combo group were subject to the addi-
tional requirement that the first prescription for each drug be 
received within 7 days of the other in order to capture the 
intent to treat with a combination of separate pills. Patients 
in the FDC group were required to have at least one Epzicom 
refill within 60 days following the index date. Likewise, 
patients in the NRTI Combo group were required to have 
at least one refill for each agent within 60 days following 
initial receipt of the agent. Individuals in both treatment 
groups were excluded from the analysis if they met any 
of the following conditions: receipt of both Epzicom and 
one or more of its components on the index date; receipt of 
alternative therapy (ie, NRTI combo for the FDC group, or 
Epzicom for the NRTI Combo group) prior to the index date; 
failure to receive a third regimen component within 7 days 
of the index date; less than 6 months of continuous health 
plan enrollment prior to the index date; less than 60 days of 
continuous health plan enrollment after the index date; and/or 
age less than 18 years on the index date. The analysis was 
not limited to ART-naïve individuals because such patients 
may not accurately reflect the clinical populations using these 
drugs. However, because experienced and naïve patients may 
differ in their adherence behaviors, we control for prior ART 
exposure in the statistical analysis.
For each patient, a follow-up period was defined as 
the period beginning with the index date and ending with 
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e  xpiration of the days’ supply for the last observed refill 
for the study therapy of interest, receipt of alternative study 
therapy (eg, Epzicom for the NRTI Combo group or vice 
versa), a gap of more than 180 days in study therapy, end 
of health plan enrollment, or end of the IHCIS database, 
whichever occurred first. Adherence to the remaining regi-
men component(s), as well as to the overall ART regimen, 
was assessed for each patient within the follow-up period. 
The remaining regimen components were categorized by 
class as PI, NRTI (excluding the NRTI backbone agents), 
NNRTI, entry inhibitor (EI), or a boosted PI. For simplicity, 
we refer to the remaining regimen component as the third 
agent. For patients who received more than three agents, 
one class among the non-NRTI backbone antiretrovirals in 
the regimen was randomly selected as the third agent for 
analysis purposes.
Adherence measure
The primary outcome evaluated in this study was treatment 
adherence to the non-NRTI-backbone regimen component 
as measured by the medication possession ratio (MPR). 
A recent systematic literature review found MPR to be the 
most widely adopted measure in published claims-based 
analyses of medication adherence (57% of all studies).17 
MPR is generally defined as the proportion of days within an 
observation period covered by the total days’ supply obtained 
for a particular study drug within the observation period:
MPR
Sum of days’ supply in observation period
Days in obser
=
v vation period
As noted in Andrade et al,17 a common observation period 
used in the MPR calculation is the number of days between 
the first dispense date and end of the days’ supply of the last 
refill for the study therapy of interest. The same observation 
period was employed here.17
Total days supplied for the third agent was calculated as 
the combined days’ supplied for all PIs, NNRTIs, EIs, and 
third NRTIs utilized during the follow-up period. We allowed 
patients to switch drugs within the same class for the third 
agent as the class in which that component was initiated (eg, 
PI to PI, NNRTI to NNRTI, etc) and control for this in the 
multivariate regressions. Table 1 presents the percentage of 
patients in each treatment group who switched within the 
third agent class (37% of the FDC group, 27% of the NRTI 
combo group). Follow-up for third component adherence 
evaluation ended upon third agent switch to a drug outside 
of the class initiated (eg, upon switch from PI to NNRTI, 
Table 1 Patient characteristics at baseline by treatment group
Treatment group
FDC NRTI Combo
N (%) N (%)
Total study sample 650 100.0 1947 100.0
Gender
  Male 550 84.6 1597 82.0
  Female 100 15.4 350 18.0
Age category
  18–34 96 14.8 329 16.9
  35–44 278 42.8 920 47.3
  45–54 205 31.5 534 27.4
  55–64 62 9.5 142 7.3
 $ 65 9 1.4 22 1.1
Geographic region*
  Northeast 263 40.5 1106 56.8
  South 237 36.5 404 20.8
  Midwest 62 9.5 114 5.9
  West 69 10.6 82 4.2
  Unknown 19 2.9 241 12.4
Insurance payer type
  Commercial 635 97.7 1895 97.3
  Medicaid 8 1.2 28 1.4
  Medicare 7 1.1 24 1.2
Insurance product type*
    Health maintenance  
organization
231 35.5 699 35.9
  Point of service plan 145 22.3 249 12.8
    Preferred provider  
organization
266 40.9 915 47.0
  Other 8 1.2 84 4.3
Year of study drug initiation*
  1997 – – 14 0.7
  1998 – – 13 0.7
  1999 – – 137 7.0
  2000 – – 185 9.5
  2001 – – 162 8.3
  2002 – – 248 12.7
  2003 – – 296 15.2
  2004 119 18.31 547 28.1
  2005 357 54.92 245 12.6
  2006 174 26.77 100 5.1
Prior ART in 6-month  
pre-index period*
370 56.92 570 29.28
MPR regimen
  Mean (SD)** 0.88 0.170 0.82 0.20
  Median (range) 0.96 0.26–1.00 0.86 0.08–1.00
  MPR $ 0.80** 502 77.2 1269 65.2
  MPR $ 0.85** 459 70.6 1126 57.8
  MPR $ 0.90** 426 65.5 953 49.0
  MPR $ 0.95** 355 54.6 766 39.3
MPR third component
  Mean (SD)** 0.92 0.168 0.85 0.245
  Median (range) 1.0 0.03–1.0 0.98 0.005–1.0
  MPR $ 0.80** 565 86.9 1460 75.0
  MPR $ 0.85** 542 83.4 1362 70.0
  MPR $ 0.90** 514 79.1 1250 64.2
  MPR $ 0.95** 478 73.5 1103 56.7
Switched within third agent class 242 37.2 522 26.8
Note: *Indicates differences between groups at P , 0.001; **P , 0.0001.
Abbreviations: ART,  antiretroviral  therapy;  FDC,  fixed-dose  combination;  MPR, 
medication possession ratio; NRTI, nucleoside reverse transcriptase inhibitor; SD, 
standard deviation.
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NNRTI to PI). Days covered by both the NRTI backbone 
and the third agent were assessed by evaluating overlapping 
days’ supply for the respective agents.
Statistical analysis
Patient characteristics were measured at the index date and 
included age, gender, geographic region, insurance payer 
type (eg, commercial, self, or government-sponsored), 
insurance product type (eg, health maintenance organiza-
tion [HMO], preferred provider organization [PPO]), prior 
exposure to antiretroviral therapy, and eligibility for mental 
health benefits coverage. We also assessed the presence of 
substance abuse and mental health disorders that have been 
linked to poor ART adherence during the 6-month period 
prior to therapy initiation. ICD-9 diagnostic and CPT-4 
procedural codes appearing in medical records were used to 
identify these conditions and were based on algorithms set 
forth by the US Substance Abuse and Mental Health Services 
Administration (SAMHSA).18
Descriptive analyses of patient characteristics and 
unadjusted adherence measures were conducted as mean 
values and standard deviations for continuous variables of 
interest and frequency distributions for categorical variables 
of   interest. The statistical significance of descriptive differ-
ences in adherence outcomes between the FDC and NRTI 
Combo groups, as well as between patients who are adherent 
and not adherent with each study therapy based on relevant 
MPR thresholds, were measured using t-tests and χ2 tests as 
appropriate, with results reported as P values.
To assess differences in adherence to the third agent 
between the FDC and NRTI Combo groups, multivariate 
regressions of the following general forms were estimated:
  MPR = β0 + β1FDC + β2Xi + ε, and  (1)
  ADHERENT = β0 + β1FDC + β2Xi + ε.  (2)
In Equation 1, continuous MPR was estimated in a linear 
model as a function of a dichotomous indicator FDC equal to 
one for patients who initiated Epzicom and zero for patients 
who initiated an NRTI backbone as separate components, and a 
vector of baseline patient characteristics (Xi). Equation 2 was a 
logistic model with the same covariate structure as Equation 1. 
The dichotomous outcome, ADHERENT, was set equal to one 
for patients meeting one of four MPR thresholds (MPR $ 0.80, 
0.85, 0.90, and 0.95) and zero for patients not meeting the 
threshold. This range of values was chosen based on p  revious 
evidence suggesting that lower risk of virologic failure is 
a  ssociated with maintaining adherence of at least 95%.5,6
All analyses were carried out using SAS® (v 9; SAS 
Institute, Cary, NC) statistical software.
Results
After applying inclusion and exclusion criteria as described 
previously, there were 650 individuals in the FDC group and 
1947 in the NRTI Combo group (Figure 1). In both groups, 
the proportions of patients receiving an NNRTI or a PI as the 
third agent of their regimens were similar (Table 2). Roughly 
59%, 42%, and 37% of patients in the NRTI group received 
lamivudine, tenofovir, or stavudine, respectively. Median 
duration of follow-up for the FDC group was 272 days; for 
the NRTI Combo group, 338 days.
The distribution of baseline (index date) characteristics 
for patients in the FDC and NRTI Combo groups is shown 
in Table 1. The majority of study subjects were aged 35–54 
years, and 82.7% were men. FDC group patients had an 
unadjusted mean adherence of 0.88 (standard deviation 
[SD] = 0.17) versus 0.82 (SD = 0.20) for the NRTI Combo, 
with median adherence of 0.96 (range: 0.26–1.00) versus 
0.89 (range: 0.08–1.00), respectively (P , 0.0001 for mean 
comparisons). Mean adherence to the third agent was 0.923 
(SD = 0.17) for the FDC group and 0.85 (SD = 0.25) for the 
NRTI Combo group (P , 0.0001).
Partial results for the multivariate regression models 
of third agent adherence, as described below, are shown 
in Table 3; full results are available upon request from the 
authors. In multivariate logistic analyses, the presence of an 
FDC NRTI backbone consistently improved the   likelihood 
of adherence at the four thresholds examined, and this 
impact was statistically significant at the 90% and 95% 
adherence thresholds. Patients in the FDC group were 47% 
more likely to achieve a clinically meaningful adherence 
level of 95% to the third agent compared to the NRTI Combo 
group. When the threshold for adherence was considered at 
the lower 90% level, the likelihood of achieving that level 
of adherence to the third agent was 40% higher among FDC 
patients. Similarly, when adherence was defined as a continu-
ous variable, use of an FDC provided a small improvement in 
adherence to the third agent compared to the use of separate 
pills (NRTI Combo), but the magnitude of the effect did not 
reach statistical significance.
Relative to the PI class, third agents that were from the 
NRTI or boosted PI classes were associated with a higher 
likelihood of adherence (or better odds of achieving a certain 
level of adherence) in all three models shown in Table 3. In 
the continuous MPR model, NRTIs were associated with an 
absolute increase in adherence of 11.6%; boosted PIs, 7.3%. 
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Entry inhibitors were consistently associated with reduced 
adherence compared to PIs, but the effect reached only 
near statistical significance in the continuous MPR model. 
Switching of the third agent within the same class was also 
consistently associated with improved adherence in all three 
models. Prior ART experience in the 6-month, pre-index 
period was insignificant across all models.
Discussion
Evidence from clinical trials and observational studies in 
a variety of therapeutic applications supports the ability of 
FDC products to improve adherence to therapy, compared 
to separate pills.7,9,19,20 To our knowledge, this is the first 
study to empirically quantify the spillover effect of FDCs 
in improving adherence to another regimen component. 
Our results confirm the hypothesis that use of an FDC as the 
backbone of an ART regimen improves adherence to the third 
agent, compared to a regimen that utilizes separate pills as 
a regimen backbone. This improvement in adherence is in 
addition to the increase associated solely with the backbone 
component of the regimen.
While some evidence suggests that newer antiretrovirals 
and ART combinations may be more “forgiving” of poor 
adherence than older agents and un-boosted regimens, the 
standard for adherence in HIV remains high.4 In our popula-
tion of managed care enrollees, patients receiving an FDC 
backbone were nearly 50% more likely to achieve an adher-
ence rate of 95% or better to the third agent in the regimen. 
Even at the lower 90% threshold, FDC backbone use was 
associated with a nearly 40% increase in the likelihood of 
Original sample
N = 23,047
FDC group
n = 2,998
No 3rd agent within 7
days of index date
Age less than 18
years
< 6 months prior
continuous
enrollment
< 60 days post
continuous
enrollment
No study drug refill
within 60 days
of initiation
Days’ supply
unavailable
n = 1,860 n = 18,981
n = 15,715
n = 14,492
n = 3,550
n = 3,261
n = 2,143
n = 1,947
n = 1,574
n = 1,568
n = 876
n = 651
n = 650
n = 978
Initiated alternative
therapy∗ before study
therapy
NRTI Combo group
n = 20,049
Figure 1 Sequential application of study inclusion and exclusion criteria to the IHCIS sample.
Note: *Alternative therapy use refers to the use of a non-study drug within the group (eg, the use of Epzicom by the NRTI Combo group).
Abbreviations: FDC, fixed-dose combination; IHCIS, Integrated Health Care Information Services; NRTI, nucleoside reverse transcriptase inhibitor.
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Table 2 Antiretroviral therapy use by treatment group
  Treatment group
FDC NRTI Combo
N (%) N (%)
NRTI Combo initiated
  Lamivudine + stavudine – – 500 25.7
  Lamivudine + tenofovir – – 377 19.4
  Tenofovir + emtricitibine – – 188 9.7
  Tenofovir + didanosine – – 125 6.4
  Lamivudine + abacavir – – 113 5.8
  Stavudine + didanosine – – 104 5.3
  Lamivudine + didanosine – – 91 4.7
  Lamivudine + zidovudine – – 70 3.6
  Tenofovir + abacavir – – 67 3.4
  Stavudine + abacavir – – 62 3.2
  Tenofovir + stavudine – – 53 2.7
  Other combinations – – 197 10.1
Thirrd ART component initiated (drug class)
  PI (alone) 194 29.9 637 32.7
  NNRTI 53 8.2 72 3.7
  NRTI* 262 40.3 987 50.7
  PI (w/ritonavir booster) 4 0.62 3 0.15
  EI 137 21.1 248 12.7
Third ART component initiated (drug name)
  Efavirenz 203 31.2 757 38.9
  Atazanavir 161 24.8 215 11.0
  Lopinavir/ritonavir FDC 67 10.3 279 14.3
  Lexiva (w/Norvir booster) 51 7.9 28 1.4
  Nevirapine 59 9.1 224 11.5
  Tenofovir 31 4.8 29 1.5
  Fosamprenavir 18 2.8 20 1.0
  Ritonavir (full-dose) 11 1.7 21 1.1
  Stavudine 8 1.2 1 0.1
  Didanosine 6 0.9 1 0.1
  Nelfinavir 7 1.1 157 8.1
  Indinavir 4 0.6 93 4.8
  Lamivudine 1 0.2 7 0.4
  Other 23 3.5 115 5.9
Note: *For the NRTI Combo group, the third NRTI initiated must be different from 
either of the two  NRTIs initiated.
Abbreviations:  NRTI,  nucleoside  reverse  transcriptase  inhibitor;  PI,  protease 
inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; EI, entry inhibitor; 
ART, antiretroviral therapy; FDC, fixed-dose combination.
third-agent adherence. The magnitude of the FDC spillover 
adherence effect observed in our sample, while smaller than 
the approximately 300% direct effect estimated by Legorreta 
et al,8 is nonetheless statistically and clinically meaningful.
Results for adherence thresholds of 80% and 85% and for 
continuous adherence were also positive, but did not reach 
statistical significance. The inability to detect a spillover 
effect in these other model specifications may reflect the 
adherence behavior of our sample. Mean regimen adher-
ence among the patients in this study was 88%, relatively 
high compared to other reports, though not unprecedented.21 
Examination of adherence effects from FDCs in patient 
p  opulations with lower baseline levels of adherence is needed 
to fully understand the spillover phenomenon.
Across the spectrum of available antiretrovirals, adher-
ence is positively correlated with virologic suppression.4 FDC 
backbones, then, may play an important role in improving 
adherence and likelihood of suppression for the remaining 
regimen component(s), regardless of drug class. A  dditionally, 
adherence plays an important role in the development of 
drug resistance, although the specific relationships may dif-
fer across drug classes.22 As such, the spillover adherence 
effect of FDCs may be especially clinically meaningful 
for PI-based regimens. Studies examining the relationship 
between adherence and resistance suggest that the develop-
ment of primary and secondary PI mutations peaks at levels 
of adherence just below those required to maintain virologic 
suppression.22,23 For example, among patients with relatively 
high overall adherence, even small, absolute improvements 
in PI adherence of only a few percentage points may be suf-
ficient to substantially reduce mutation development. The use 
of an FDC backbone may be one tool for achieving such an 
improvement in PI adherence.
The use of administrative records to examine the spillover 
effect of FDCs offers several advantages over other data 
sources. First, these data reflect the experiences of patients 
in actual clinical practice, potentially avoiding the adherence 
bias associated with clinical trials.24 Second, these observa-
tional data allow for a relatively large sample size, thereby 
increasing the ability to detect differences between study 
groups. Additionally, while not a nationally representative 
sample, the IHCIS data include individuals from all regions of 
the US. To the extent that heterogeneity in adherence is cor-
related with regional heterogeneity in HIV risk, demographic 
characteristics, and other factors that may affect adherence, 
the generalizability of our results is improved relative to 
smaller studies of more homogeneous cohorts.
There are differences between the IHCIS sample, and 
the US HIV population as a whole. In 2006, approximately 
73% of individuals living with a diagnosis of HIV or AIDS 
in the US in 2006 were males, compared to nearly 83% in our 
study.25 During the same time period, roughly 38% of persons 
living with HIV/AIDS were aged 18–34 years, compared to 
less than 15% in our sample. The older age and increased 
proportion of males observed in our sample may reflect an 
increased access to health insurance for this group compared 
to other individuals diagnosed with HIV/AIDS. It is possible 
that spillover effects measured in different populations may 
differ from those seen in the IHCIS sample, especially if fac-
tors associated with insurance status, such as education and 
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income (which are unobserved in the IHCIS sample), also 
influence adherence behavior. While socioeconomic status 
does appear to be associated with adherence in many chronic 
diseases, such relationships have not been documented con-
clusively for HIV .26
As with other observational studies, this work is subject 
to limitations which should be considered when evaluating 
the results. The retrospective nature of the data source raises 
the possibility of selection bias because the assignment of 
patients to study groups is not random, as in a clinical trial. 
For example, if individuals who received Epzicom were 
more likely to be adherent to a third regimen component 
than those who received a backbone of separate NRTIs, 
the impact of FDCs on spillover adherence would be 
  overestimated.   Conversely, if physicians who were particu-
larly concerned with patient adherence tended to prescribe 
FDCs to that end, then the spillover effect observed here may 
be   underestimated. It should be noted that the study inclusion 
requirement of at least one refill in the 60 days following the 
index   prescription – necessary to capture the intent to treat 
Table 3 Results of multivariate regression analyses on third component adherence
Covariates Continuous MPR MPR $ 90% MPR $ 95%
Parameter  
estimate (SE)
P value Odds ratio 95% CI Odds ratio 95% CI
FDC group (vs NRTI Combo) 0.0155 (0.0132) 0.2406 1.40 1.05–1.86 1.47 1.12–1.94
Male (vs Female) 0.0133 (0.0116) 0.2545 1.21 0.95–1.53 1.25 0.99–1.57
Age (vs 18–34)
  35–44 0.0047 (0.0125) 0.7042 0.90 0.70–1.16 0.86 0.67–1.11
  45–54 0.0173 (0.0134) 0.2010 1.04 0.79–1.37 0.98 0.75–1.29
  55–64 0.0257 (0.0189) 0.1729 0.95 0.64–1.40 1.13 0.77–1.66
 $ 65 0.0822 (0.0420) 0.0507 1.47 0.60–3.58 1.67 0.70–3.96
Location (vs Northeast)
  South –0.0236 (0.0127) 0.0631 0.68 0.53–0.89 0.65 0.50–0.84
  Midwest 0.0258 (0.0189) 0.1739 1.37 0.91–2.01 1.00 0.68–1.46
  West 0.0404 (0.0205) 0.0489 1.48 0.94–2.32 1.24 0.81–1.89
  Unknown 0.0043 (0.0153) 0.7784 1.07 0.78–1.45 0.90 0.67–1.22
Commercial payer (vs public) 0.0733 (0.0293) 0.0125 2.93 1.61–5.31 2.19 1.20–3.98
Plan type (vs POS)
  HMO 0.0065 (0.0141) 0.6445 1.17 0.87–1.57 1.18 0.89–1.58
  PPO –0.0091 (0.0136) 0.5052 0.95 0.72–1.27 0.98 0.74–1.30
  Other –0.0180 (0.0266) 0.4998 1.12 0.65–1.94 1.27 0.74–2.17
Year of ART initiation (vs 1997)
  1998 –0.0698 (0.0843) 0.4077 0.74 0.15–3.55 0.52 0.10–2.65
  1999 –0.1324 (0.0630) 0.0355 0.40 0.12–1.33 0.56 0.17–1.81
  2000 –0.1309 (0.0624) 0.0361 0.47 0.14–1.56 0.56 0.17–1.81
  2001 –0.1625 (0.0626) 0.0095 0.34 0.10–1.14 0.50 0.15–1.62
  2002 –0.1405 (0.0617) 0.0229 0.38 0.12–1.24 0.54 0.17–1.73
  2003 –0.0854 (0.0616) 0.1657 0.57 0.17–1.87 0.82 0.7360
  2004 –0.0419 (0.0602) 0.4859 0.87 0.27–2.77 1.18 0.38–3.67
  2005 –0.0356 (0.0604) 0.5553 0.80 0.25–2.57 0.97 0.31–3.02
  2006 –0.0026 (0.0614) 0.9664 1.09 0.33–3.60 1.38 0.43–4.43
Eligible for MH benefits 0.0152 (0.0140) 0.2780 1.26 0.94–1.69 1.14 0.86–1.52
Prior diagnoses (vs None)
  Prior MH 0.0100 (0.0124) 0.4180 1.36 1.04–1.77 1.55 1.20–2.00
  Prior SA –0.0095 (0.0493) 0.8477 1.23 0.41–3.68 1.30 0.45–3.77
  Prior MH + SA 0.0177 (0.0650) 0.7856 0.79 0.19–3.32 0.64 0.16–2.53
Third agent class (vs PI)
  NRTI 0.1164 (0.0242) ,0.0001 10.56 4.09–27.25 9.74 4.06–23.35
  NNRTI 0.0177 (0.0103) 0.0861 1.11 0.91–1.35 1.12 0.93–1.36
  EI –0.1623 (0.0834) 0.0518 0.74 0.16–3.52 0.62 0.13–2.87
  Boosted PI 0.0731 (0.0182) ,0.0001 4.83 2.95–7.91 5.45 3.36–8.84
Switched within third agent class 0.0476 (0.0153) 0.0019 1.72 1.27–2.33 2.21 1.64–2.97
Prior ART in 6-month pre-index period –0.0147 (0.0095) 0.1217 0.98 0.81–1.19 1.01 0.84–1.23
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; EI, entry inhibitor; FDC, fixed-dose combination; HMO, health maintenance organization; MH, mental 
health; MPR, medication possession ratio; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; 
POS, point of service; PPO, preferred provider organization; SA, substance abuse; SE, standard error.
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with a specific agent – may bias the sample toward more 
adherent patients. In such a case, the ability of the FDC to 
improve adherence even among those already adherent is 
notable. Still, further efforts are needed to understand adher-
ence among very poor adherers.
As noted in Table 1, subjects in the two study groups 
were similar in terms of age and gender, but other differ-
ences did exist. We controlled for all the factors listed in 
Table 1 in our statistical analysis. We did not have access 
to subjects’ complete HIV treatment histories and could 
not definitively identify those who were completely naïve 
to treatment. While there is some evidence that adherence 
differs between treatment-experienced and treatment-naïve 
patients,27 the likelihood that the marginal adherence effect 
estimated here would differ between these two groups of 
patients was less likely and, indeed, was what we observed. 
There may exist other factors for which we were unable to 
control. If those factors were associated with adherence 
differentially by study group, the study results may be 
biased.
Epzicom dosing is labeled as once per day, while most 
other NRTI combinations used during the study period 
were dosed twice per day, per product labeling. Thus, 
some of the spillover attributed to the FDC group may be 
due to reduced dosing frequency. However, some of the 
combinations in the NRTI Combo group included one or 
two agents that could be dosed once per day. Interestingly, 
patients in the NRTI Combo were more likely to receive 
an NNRTI as the third regimen component. Compared 
to PIs, NNRTIs have been associated with improved   
adherence.28
The approach we use to construct the follow-up period 
over which adherence was assessed is subject to the inher-
ent limitation that some patients may discontinue study 
therapy before expiration of the last observed refill. Since 
discontinuation in that case cannot be observed in auto-
mated pharmacy claims, our method may lead to follow-up 
durations that are slightly overestimated for some patients. 
Similarly, no gold standard for measurement of adherence 
exists. Adherence levels measured from pharmacy records 
have been shown to be higher than those measured by elec-
tronic monitoring, although the two measures are highly 
correlated.29 I  mportantly, any overestimation of adherence 
would be attributable to both study groups, minimizing 
its effect.
This study examines only the use of an FDC containing 
two antiretrovirals and intended to be combined with at least 
one additional agent. Due to sample size constraints, we 
were unable to assess whether spillover effects extend to all 
components of regimens that consist of an FDC plus two or 
more antiretrovirals taken as separate pills. FDCs co  ntaining 
three antiretrovirals are also available and can be used alone 
or as part of a larger regimen in combination with other 
antiretrovirals. It is unclear, a priori, whether such effects 
would be greater or lesser than those seen with two-agent 
FDCs in a typical, three-agent regimen. We have shown that 
adherence to a third regimen component is increased with 
the use of an FDC backbone and that this adherence level 
is high. As a result, in populations where medication-taking 
behavior is relatively high, triple-agent FDCs may not offer 
much of an adherence advantage over dual-agent FDCs. 
Additional research on the direct and spillover adherence 
effects of dual-agent and triple-agent FDCs as components 
of regimens consisting of more than three antiretrovirals 
is warranted.
Successful HIV therapy requires individuals to maintain 
nearly perfect adherence, and clinical practice guidelines 
have long recommended that physicians consider adherence 
when selecting regimen components. This study highlights 
an additional adherence advantage associated with the use 
of FDCs that has not previously been identified: a spillover 
effect on a non-fixed regimen component. While additional 
efforts are needed to assess the extent of adherence spillover 
associated with other FDCs, our work supports the use of 
fixed-dose NRTI backbones as a means of encouraging 
adherence to the entire ART regimen.
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